Works matching IS 01676997 AND DT 2022 AND VI 40 AND IP 6

Results: 23

Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1282, doi. 10.1007/s10637-022-01293-9

By:

Shen, Peng;
Qiao, Bo;
Jin, Nenghao;
Wang, Shuyan

Publication type:

Article

A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1306, doi. 10.1007/s10637-022-01311-w

By:

Rajdev, Lakshmi;
Lee, Ju-Whei;
Libutti, Steven K.;
Benson, Al B.;
Fisher Jr, George A.;
Kunz, Pamela L.;
Hendifar, Andrew E.;
Catalano, Paul;
O'Dwyer, Peter J.

Publication type:

Article

Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1298, doi. 10.1007/s10637-022-01310-x

By:

Sumi, Toshiyuki;
Koshshino, Yuta;
Sekikawa, Motoki;
Nagahisa, Yuta;
Matsuura, Keigo;
Shijubou, Naoki;
Kamada, Koki;
Watanabe, Hiroki;
Michimata, Haruhiko;
Nagayama, Daiki;
Tanaka, Yusuke;
Yamada, Yuichi;
Chiba, Hirofumi

Publication type:

Article

CD25-targeted antibody–drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1333, doi. 10.1007/s10637-022-01300-z

By:

Xu, Bo;
Li, Shaoqian;
Kang, Bo;
Fan, Shangzhi;
He, Zunbo;
Zhou, Jiecan

Publication type:

Article

Tetra-arsenic tetra-sulfide enhances NK-92MI mediated cellular immunotherapy in all-trans retinoic acid-resistant acute promyelocytic leukemia.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1231, doi. 10.1007/s10637-022-01313-8

By:

Liu, Yanfeng;
Jia, Yan;
Liu, Yi;
Chen, Xuefeng;
Zhang, Mei

Publication type:

Article

TRIM59 guards ER proteostasis and prevents Bortezomib-mediated colorectal cancer (CRC) cells' killing.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1244, doi. 10.1007/s10637-022-01306-7

By:

Feng, Xuejia;
Yang, Gui;
Zhang, Litian;
Tao, Shishi;
SHIM, Joong Sup;
Chen, Liang;
Wu, Qingxia

Publication type:

Article

Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1290, doi. 10.1007/s10637-022-01303-w

By:

Tamaki, Nobuharu;
Tada, Toshifumi;
Kurosaki, Masayuki;
Yasui, Yutaka;
Ochi, Hironori;
Mashiba, Toshie;
Sakamoto, Azusa;
Marusawa, Hiroyuki;
Narita, Ryoichi;
Uchida, Yasushi;
Akahane, Takehiro;
Kondo, Masahiko;
Mori, Nami;
Takaki, Shintaro;
Tsuji, Keiji;
Kobashi, Haruhiko;
Kusakabe, Atsunori;
Furuta, Koichiro;
Arai, Hirotaka;
Nonogi, Michiko

Publication type:

Article

Long-term response in a patient with adenocarcinoma harboring both common and uncommon EGFR mutations.

Published in:

2022

By:

Okauchi, Shinichiro;
Satoh, Hiroaki

Publication type:

Letter

EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1342, doi. 10.1007/s10637-022-01301-y

By:

Ogusu, Shinsuke;
Ariyasu, Ryo;
Akita, Takahiro;
Kiritani, Ayu;
Tsugitomi, Ryosuke;
Amino, Yoshiaki;
Uchibori, Ken;
Kitazono, Satoru;
Yanagitani, Noriko;
Nishio, Makoto

Publication type:

Article

Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1315, doi. 10.1007/s10637-022-01305-8

By:

Sumi, Toshiyuki;
Sekikawa, Motoki;
Nagahisa, Yuta;
Matsuura, Keigo;
Shijubou, Naoki;
Kamada, Koki;
Watanabe, Hiroki;
Yamada, Yuichi;
Tanaka, Yusuke;
Chiba, Hirofumi

Publication type:

Article

Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1254, doi. 10.1007/s10637-022-01304-9

By:

Yokota, Hayato;
Sato, Kazuhiro;
Sakamoto, Sho;
Okuda, Yuji;
Fukuda, Natsuki;
Asano, Mariko;
Takeda, Masahide;
Nakayama, Katsutoshi;
Miura, Masatomo

Publication type:

Article

Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2<sup>V617F</sup> and ASXL1 mutations.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1194, doi. 10.1007/s10637-022-01297-5

By:

Yuan, Jiajia;
Song, Junzhe;
Chen, Chao;
Lv, Xue;
Bai, Jie;
Yang, Jing;
Zhou, Yuan

Publication type:

Article

Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1274, doi. 10.1007/s10637-022-01299-3

By:

Hu, Linlin;
Cai, Mingmin;
Qian, Wei;
Dou, Ting;
Sun, Qiuyue;
Tang, Lu;
Wang, Huiping

Publication type:

Article

Correction to: Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine.

Published in:

2022

By:

Ping, Haiqin;
Yu, Wenjun;
Gong, Xiaoming;
Tong, Xin;
Lin, Cheyu;
Chen, Zhaojun;
Cai, Caiyun;
Guo, Kai;
Ke, Hengning

Publication type:

Correction Notice

Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1185, doi. 10.1007/s10637-022-01294-8

By:

Toumia, Imene Ben;
Ponassi, Marco;
Barboro, Paola;
Iervasi, Erika;
Vargas, Gabriela Coronel;
Banelli, Barbara;
Fiordoro, Stefano;
Ghedira, Leila Chekir;
Kohnke, Franz Heinrich;
Izzotti, Alberto;
Rosano, Camillo

Publication type:

Article

BMP2 as a promising anticancer approach: functions and molecular mechanisms.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1322, doi. 10.1007/s10637-022-01298-4

By:

Li, Tong-tong;
Lai, Yong-wei;
Han, Xu;
Niu, Xin;
Zhang, Peng-xia

Publication type:

Article

Correction to: A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: A case report.

Published in:

2022

By:

Wang, Chunguang;
Chen, Shu;
He, Qianru;
Sun, Tingting;
Xu, Peiran

Publication type:

Correction Notice

Ketamine promotes breast tumor growth in a mouse breast tumor model involving with high expression of miR-27b-3p and EGFR.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1165, doi. 10.1007/s10637-022-01291-x

By:

Chen, Li-Kuei;
Shih, Chien-Hung;
Chen, Shiou-Sheng;
Huang, Zi-Xuan;
Chang, Yu-Jung;
Chen, Linyi;
Chuang, Tsung-Hsien;
Chen, Kuen-Bao

Publication type:

Article

Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1173, doi. 10.1007/s10637-022-01290-y

By:

Ping, Haiqin;
Yu, Wenjun;
Gong, Xiaoming;
Tong, Xin;
Lin, Cheyu;
Chen, Zhaojun;
Cai, Caiyun;
Guo, Kai;
Ke, Hengning

Publication type:

Article

Carbidopa suppresses estrogen receptor-positive breast cancer via AhR-mediated proteasomal degradation of ERα.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1216, doi. 10.1007/s10637-022-01289-5

By:

Chen, Zhiwei;
Xia, Xing;
Chen, Heyan;
Huang, Huirong;
An, Xingsi;
Sun, Meng;
Yao, Qing;
Kim, Kwonseop;
Zhang, Hailin;
Chu, Maoping;
Chen, Ruijie;
Bhutia, Yangzom D.;
Ganapathy, Vadivel;
Kou, Longfa

Publication type:

Article

Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1263, doi. 10.1007/s10637-022-01281-z

By:

Calvo, Emiliano;
Sessa, Cristiana;
Harada, Guilherme;
de Miguel, Maria;
Kahatt, Carmen;
Luepke-Estefan, Xarles Erik;
Siguero, Mariano;
Fernandez-Teruel, Carlos;
Cullell-Young, Martin;
Stathis, Anastasios;
Drilon, Alexander

Publication type:

Article

Comparison of dual mTORC1/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of breast cancer cells using proton nuclear magnetic resonance spectroscopy metabolomics.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1206, doi. 10.1007/s10637-022-01268-w

By:

Ni, Zhitao;
Xu, Shaolin;
Yu, Zheng;
Ye, Zhongjiang;
Li, Rongqi;
Chen, Chuang;
Yang, Jianhui;
Liu, Huamin;
Zhou, Ziye;
Zhang, Xiuhua

Publication type:

Article

A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report.

Published in:

Investigational New Drugs, 2022, v. 40, n. 6, p. 1350, doi. 10.1007/s10637-022-01262-2

By:

Wang, Chunguang;
Chen, Shu;
He, Qianru;
Sun, Tingting;
Xu, Peiran

Publication type:

Article